Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Collagen type IV alpha-3-4-5 network is a specialized extracellular matrix scaffold that forms the structural backbone of the mature glomerular basement membrane (GBM) in the kidney, as well as basement membranes in the cochlea and eye. Composed of heterotrimers of the alpha-3, alpha-4, and alpha-5 chains of type IV collagen (encoded by the COL4A3, COL4A4, and COL4A5 genes), this network replaces the developmental alpha-1-1-2 network during glomerular maturation to provide superior mechanical stability and permselectivity. Mutations in any of these three genes disrupt the assembly of the network, leading to Alport syndrome, a progressive hereditary nephritis characterized by GBM lamellation, hematuria, proteinuria, and eventual end-stage renal disease, often accompanied by sensorineural hearing loss and ocular defects. Additionally, the non-collagenous (NC1) domain of the alpha-3 chain serves as the primary autoantigen in Goodpasture syndrome (anti-GBM disease), where pathogenic autoantibodies trigger rapidly progressive glomerulonephritis and pulmonary hemorrhage. Therapeutic strategies targeting this network include standard-of-care RAAS inhibitors (such as ramipril and losartan) and SGLT2 inhibitors (such as dapagliflozin) to reduce mechanical strain, immunosuppressive regimens (such as cyclophosphamide and rituximab) to suppress autoantibody production in Goodpasture syndrome, and emerging nonsense mutation read-through therapies (such as exaluren/ELX-02) designed to restore full-length collagen IV expression.
Restoration of the structural network through nonsense mutation read-through therapy (e.g., exaluren/ELX-02); stabilization of mutant collagen folding via chemical chaperones; reduction of intraglomerular pressure and proteinuria via RAAS and SGLT2 inhibition; and removal or suppression of autoantibodies in autoimmune disease.
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen type IV alpha-3-4-5 network (Collagen IV α345).